{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:24:14Z","timestamp":1779380654000,"version":"3.53.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Applied DNA","award":["Applied DNA"],"award-info":[{"award-number":["Applied DNA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00705-023-05746-1","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T09:03:17Z","timestamp":1680080597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A linear SARS-CoV-2 DNA vaccine candidate reduces virus shedding in ferrets"],"prefix":"10.1007","volume":"168","author":[{"given":"Mathias","family":"Martins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela M.","family":"do Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Conforti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C. G.","family":"Noll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Impellizeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Lione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Salvatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Compagnone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Viscount","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hayward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clay","family":"Shorrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Aurisicchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3237-8940","authenticated-orcid":false,"given":"Diego G.","family":"Diel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"5746_CR1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","volume":"395","author":"C Wang","year":"2020","unstructured":"Wang C, Horby PW, Hayden FG, Gao GF (2020) A novel coronavirus outbreak of global health concern. Lancet 395:470\u2013473. https:\/\/doi.org\/10.1016\/S0140-6736(20)30185-9","journal-title":"Lancet"},{"key":"5746_CR2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2001017","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W et al (2020) A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa2001017","journal-title":"N Engl J Med"},{"key":"5746_CR3","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","volume":"395","author":"JFW Chan","year":"2020","unstructured":"Chan JFW, Yuan S, Kok KH et al (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395:514\u2013523. https:\/\/doi.org\/10.1016\/S0140-6736(20)30154-9","journal-title":"Lancet"},{"key":"5746_CR4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, Zhou M, Dong X et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395:507\u2013513. https:\/\/doi.org\/10.1016\/S0140-6736(20)30211-7","journal-title":"Lancet"},{"key":"5746_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7","author":"P Zhou","year":"2020","unstructured":"Zhou P, Yang X, Lou, Wang XG et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. https:\/\/doi.org\/10.1038\/s41586-020-2012-7","journal-title":"Nature"},{"key":"5746_CR6","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41564-020-0771-4","volume":"5","author":"MF Boni","year":"2020","unstructured":"Boni MF, Lemey P, Jiang X et al (2020) Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. Nat Microbiol 5:1408\u20131417. https:\/\/doi.org\/10.1038\/s41564-020-0771-4","journal-title":"Nat Microbiol"},{"key":"5746_CR7","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1016\/j.cell.2021.08.017","volume":"184","author":"EC Holmes","year":"2021","unstructured":"Holmes EC, Goldstein SA, Rasmussen AL et al (2021) The origins of SARS-CoV-2: A critical review. Cell 184:4848\u20134856. https:\/\/doi.org\/10.1016\/j.cell.2021.08.017","journal-title":"Cell"},{"key":"5746_CR8","unstructured":"Gorbalenya AE, Baker SC, Baric RS et al (2020) The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol"},{"key":"5746_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","volume":"3","author":"F Li","year":"2016","unstructured":"Li F (2016) Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol 3:237\u2013261. https:\/\/doi.org\/10.1146\/annurev-virology-110615-042301","journal-title":"Annu Rev Virol"},{"key":"5746_CR10","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.1073\/pnas.0809524106","volume":"106","author":"S Belouzard","year":"2009","unstructured":"Belouzard S, Chu VC, Whittaker GR (2009) Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci U S A 106:5871\u20135876. https:\/\/doi.org\/10.1073\/pnas.0809524106","journal-title":"Proc Natl Acad Sci USA"},{"key":"5746_CR11","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1254\/fpj.147.120","volume":"426","author":"W Li","year":"2003","unstructured":"Li W, Moore MJ, Natalya et al (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450\u2013454. https:\/\/doi.org\/10.1254\/fpj.147.120","journal-title":"Nature"},{"key":"5746_CR12","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1128\/JVI.02615-14","volume":"89","author":"F Li","year":"2015","unstructured":"Li F (2015) Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural Studies. J Virol 89:1954\u20131964","journal-title":"J Virol"},{"key":"5746_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41423-020-0458-z","volume":"17","author":"C Yi","year":"2020","unstructured":"Yi C, Sun X, Ye J et al (2020) Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol Immunol 17:621\u2013630. https:\/\/doi.org\/10.1038\/s41423-020-0458-z","journal-title":"Cell Mol Immunol"},{"key":"5746_CR14","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/nejmoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 383:2603\u20132615. https:\/\/doi.org\/10.1056\/nejmoa2034577","journal-title":"N Engl J Med"},{"key":"5746_CR15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/nejmoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B et al (2021) Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 384:403\u2013416. https:\/\/doi.org\/10.1056\/nejmoa2035389","journal-title":"N Engl J Med"},{"key":"5746_CR16","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/nejmoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, Gray G, Vandebosch A et al (2021) Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med 384:2187\u20132201. https:\/\/doi.org\/10.1056\/nejmoa2101544","journal-title":"N Engl J Med"},{"key":"5746_CR17","unstructured":"WHO (World Health Organization) (2022) COVID19 vaccine tracker. In: WHO"},{"key":"5746_CR18","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S0140-6736(22)00151-9","volume":"399","author":"A Khobragade","year":"2022","unstructured":"Khobragade A, Bhate S, Ramaiah V et al (2022) Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. Lancet 399:1313\u20131321. https:\/\/doi.org\/10.1016\/S0140-6736(22)00151-9","journal-title":"Lancet"},{"key":"5746_CR19","doi-asserted-by":"publisher","first-page":"5751","DOI":"10.1016\/j.vaccine.2016.10.001","volume":"34","author":"Z Sheng","year":"2016","unstructured":"Sheng Z, Gao N, Cui X et al (2016) Electroporation enhances protective immune response of a DNA vaccine against Japanese encephalitis in mice and pigs. Vaccine 34:5751\u20135757. https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.001","journal-title":"Vaccine"},{"key":"5746_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1600-065X.2010.00980.x","volume":"239","author":"MA Liu","year":"2011","unstructured":"Liu MA (2011) DNA vaccines: An historical perspective and view to the future. Immunol Rev 239:62\u201384. https:\/\/doi.org\/10.1111\/j.1600-065X.2010.00980.x","journal-title":"Immunol Rev"},{"key":"5746_CR21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.coi.2011.03.008","volume":"23","author":"NY Sardesai","year":"2011","unstructured":"Sardesai NY, Weiner DB (2011) Electroporation delivery of DNA vaccines: Prospects for success. Curr Opin Immunol 23:421\u2013429. https:\/\/doi.org\/10.1016\/j.coi.2011.03.008","journal-title":"Curr Opin Immunol"},{"key":"5746_CR22","doi-asserted-by":"crossref","unstructured":"Wang B, Godillot AP, Madaio MP et al (1997) Vaccination against pathogenic cells by DNA inoculation","DOI":"10.1007\/978-3-642-80475-5_2"},{"key":"5746_CR23","first-page":"765","volume":"18","author":"W Wolfgang","year":"2007","unstructured":"Wolfgang W, Leitner H, Ying and NPR (2007) DNA and RNA vaccines\u2014progress and prospects. Vaccine 18:765\u2013777","journal-title":"Vaccine"},{"key":"5746_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1586\/erv.11.188","volume":"11","author":"F Saade","year":"2012","unstructured":"Saade F, Petrovsky N (2012) Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines 11:189\u2013209. https:\/\/doi.org\/10.1586\/erv.11.188","journal-title":"Expert Rev Vaccines"},{"key":"5746_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-022-00482-0","volume":"7","author":"T-T Tzeng","year":"2022","unstructured":"Tzeng T-T, Chai KM, Shen K-Y et al (2022) A DNA vaccine candidate delivered by an electroacupuncture machine provides protective immunity against SARS-CoV-2 infection. npj Vaccines 7:1\u201312. https:\/\/doi.org\/10.1038\/s41541-022-00482-0","journal-title":"npj Vaccines"},{"key":"5746_CR26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ymthe.2021.09.011","volume":"30","author":"A Conforti","year":"2022","unstructured":"Conforti A, Marra E, Palombo F et al (2022) COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models. Mol Ther 30:311\u2013326. https:\/\/doi.org\/10.1016\/j.ymthe.2021.09.011","journal-title":"Mol Ther"},{"key":"5746_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.tvjl.2016.05.015","volume":"217","author":"J Impellizeri","year":"2016","unstructured":"Impellizeri J, Aurisicchio L, Forde P, Soden DM (2016) Electroporation in veterinary oncology. Vet J 217:18\u201325. https:\/\/doi.org\/10.1016\/j.tvjl.2016.05.015","journal-title":"Vet J"},{"key":"5746_CR28","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01455-21","author":"M Martins","year":"2022","unstructured":"Martins M, Fernandes MHV, Joshi LR, Diel DG (2022) Age-related susceptibility of ferrets to SARS-CoV-2 infection. J Virol. https:\/\/doi.org\/10.1128\/JVI.01455-21","journal-title":"J Virol"},{"key":"5746_CR29","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00083-21","author":"MV Palmer","year":"2021","unstructured":"Palmer MV, Martins M, Falkenberg S et al (2021) Susceptibility of white-tailed deer (Odocoileus virginianus) to SARS-CoV-2. J Virol. https:\/\/doi.org\/10.1128\/jvi.00083-21","journal-title":"J Virol"},{"key":"5746_CR30","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00961-22","author":"M Martins","year":"2022","unstructured":"Martins M, do Nascimento GM, Nooruzzaman M, Yuan F, Chen C, Caserta LC, Miller AD, Whittaker GR, Fang YDD (2022) The Omicron Variant BA.1.1 Presents a Lower Pathogenicity than B.1 D614G and Delta Variants in a Feline Model of SARS-CoV-2 Infection. J Virol. https:\/\/doi.org\/10.1128\/jvi.00961-22","journal-title":"J Virol"},{"key":"5746_CR31","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02370-20","author":"G Dagotto","year":"2021","unstructured":"Dagotto G, Mercado NB, Martinez DR et al (2021) Comparison of subgenomic and total RNA in SARS-CoV-2-challenged rhesus macaques. J Virol. https:\/\/doi.org\/10.1128\/jvi.02370-20","journal-title":"J Virol"},{"key":"5746_CR32","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.ymthe.2020.06.007","volume":"28","author":"A Conforti","year":"2020","unstructured":"Conforti A, Marra E, Roscilli G et al (2020) Are Genetic Vaccines the Right Weapon against COVID-19? Mol Ther 28:1555\u20131556. https:\/\/doi.org\/10.1016\/j.ymthe.2020.06.007","journal-title":"Mol Ther"},{"key":"5746_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fmedt.2020.571030","author":"Z Xu","year":"2020","unstructured":"Xu Z, Patel A, Tursi NJ et al (2020) Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases. Front Med Technol. https:\/\/doi.org\/10.3389\/fmedt.2020.571030","journal-title":"Front Med Technol"},{"key":"5746_CR34","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1016\/j.vaccine.2010.12.057","volume":"29","author":"F Lin","year":"2011","unstructured":"Lin F, Shen X, McCoy JR et al (2011) A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle. Vaccine 29:6771\u20136780. https:\/\/doi.org\/10.1016\/j.vaccine.2010.12.057","journal-title":"Vaccine"},{"key":"5746_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.03.023","author":"Y Kim","year":"2020","unstructured":"Kim Y, Il, Kim SG, Kim SM et al (2020) Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. Cell Host Microbe. https:\/\/doi.org\/10.1016\/j.chom.2020.03.023","journal-title":"Cell Host Microbe"},{"key":"5746_CR36","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.virol.2015.03.017","volume":"479\u2013480","author":"T Enkirch","year":"2015","unstructured":"Enkirch T, von Messling V (2015) Ferret models of viral pathogenesis. Virology 479\u2013480:259\u2013270. https:\/\/doi.org\/10.1016\/j.virol.2015.03.017","journal-title":"Virology"},{"key":"5746_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/v13040678","author":"M Rioux","year":"2021","unstructured":"Rioux M, Francis ME, Swan CL et al (2021) The intersection of age and influenza severity: Utility of ferrets for dissecting the age-dependent immune responses and relevance to age-specific vaccine development. Viruses. https:\/\/doi.org\/10.3390\/v13040678","journal-title":"Viruses"},{"key":"5746_CR38","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1354\/vp.45-4-551","volume":"562","author":"JMA van den Brand","year":"2008","unstructured":"van den Brand JMA, Leijten haagmans L, Riel V, Martina (2008) Pathology of Experimental SARS Coronavirus Infection in. Vet Pathol 562:551\u2013562","journal-title":"Vet Pathol"},{"key":"5746_CR39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jcpa.2014.01.004","volume":"151","author":"JMA van den Brand","year":"2014","unstructured":"van den Brand JMA, Haagmans BL, van Riel D et al (2014) The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models. J Comp Pathol 151:83\u2013112. https:\/\/doi.org\/10.1016\/j.jcpa.2014.01.004","journal-title":"J Comp Pathol"},{"key":"5746_CR40","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1177\/03009858211071012","volume":"59","author":"M Ciurkiewicz","year":"2022","unstructured":"Ciurkiewicz M, Armando F, Schreiner T et al (2022) Ferrets are valuable models for SARS-CoV-2 research. Vet Pathol 59:661\u2013672. https:\/\/doi.org\/10.1177\/03009858211071012","journal-title":"Vet Pathol"},{"key":"5746_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-021-00315-6","volume":"6","author":"GA Marsh","year":"2021","unstructured":"Marsh GA, McAuley AJ, Au GG et al (2021) ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets. npj Vaccines 6:1\u20138. https:\/\/doi.org\/10.1038\/s41541-021-00315-6","journal-title":"npj Vaccines"},{"key":"5746_CR42","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","volume":"586","author":"N van Doremalen","year":"2020","unstructured":"van Doremalen N, Lambe T, Spencer A et al (2020) ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 586:578\u2013582. https:\/\/doi.org\/10.1038\/s41586-020-2608-y","journal-title":"Nature"},{"key":"5746_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-21444-5","volume":"12","author":"AK Wheatley","year":"2021","unstructured":"Wheatley AK, Juno JA, Wang JJ et al (2021) Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun 12:1\u201311. https:\/\/doi.org\/10.1038\/s41467-021-21444-5","journal-title":"Nat Commun"},{"key":"5746_CR44","doi-asserted-by":"publisher","first-page":"6588","DOI":"10.1002\/jmv.27214","volume":"93","author":"QA Al Khames Aga","year":"2021","unstructured":"Al Khames Aga QA, Alkhaffaf WH, Hatem TH et al (2021) Safety of COVID-19 vaccines. J Med Virol 93:6588\u20136594. https:\/\/doi.org\/10.1002\/jmv.27214","journal-title":"J Med Virol"},{"key":"5746_CR45","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s12291-021-00968-z","volume":"36","author":"RJ Kaur","year":"2021","unstructured":"Kaur RJ, Dutta S, Bhardwaj P et al (2021) Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. Indian J Clin Biochem 36:427\u2013439. https:\/\/doi.org\/10.1007\/s12291-021-00968-z","journal-title":"Indian J Clin Biochem"},{"key":"5746_CR46","doi-asserted-by":"publisher","first-page":"12672","DOI":"10.1128\/jvi.78.22.12672-12676.2004","volume":"78","author":"H Weingartl","year":"2004","unstructured":"Weingartl H, Czub M, Czub S et al (2004) Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory Syndrome Is Associated with Enhanced Hepatitis in Ferrets. J Virol 78:12672\u201312676. https:\/\/doi.org\/10.1128\/jvi.78.22.12672-12676.2004","journal-title":"J Virol"},{"key":"5746_CR47","doi-asserted-by":"publisher","first-page":"6337","DOI":"10.4049\/jimmunol.181.9.6337","volume":"181","author":"F Yasui","year":"2008","unstructured":"Yasui F, Kai C, Kitabatake M et al (2008) Prior Immunization with Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus (SARS-CoV) Nucleocapsid Protein Causes Severe Pneumonia in Mice Infected with SARS-CoV. J Immunol 181:6337\u20136348. https:\/\/doi.org\/10.4049\/jimmunol.181.9.6337","journal-title":"J Immunol"},{"key":"5746_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035421","author":"C Tseng","year":"2012","unstructured":"Tseng C, Te, Sbrana E, Iwata-Yoshikawa N et al (2012) Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0035421","journal-title":"PLoS ONE"},{"key":"5746_CR49","doi-asserted-by":"publisher","first-page":"12201","DOI":"10.1128\/jvi.06048-11","volume":"85","author":"M Bolles","year":"2011","unstructured":"Bolles M, Deming D, Long K et al (2011) A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge. J Virol 85:12201\u201312215. https:\/\/doi.org\/10.1128\/jvi.06048-11","journal-title":"J Virol"},{"key":"5746_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.123158","volume":"4","author":"L Liu","year":"2019","unstructured":"Liu L, Wei Q, Lin Q et al (2019) Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI insight 4:1\u201319. https:\/\/doi.org\/10.1172\/jci.insight.123158","journal-title":"JCI Insight"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-023-05746-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-023-05746-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-023-05746-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T05:01:06Z","timestamp":1681794066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-023-05746-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["5746"],"URL":"https:\/\/doi.org\/10.1007\/s00705-023-05746-1","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]},"assertion":[{"value":"16 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.C. is an Evvivax employee. L.L., E.S., and L.A. are Takis employees. Takis and Rottapharm Biotech are jointly developing COVID-eVax. B.V., J.H., and C.S. are employees of Applied DNA Sciences and LineaRx, which retain the IP rights for the linear DNA platform.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"124"}}